DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

News

Y-mAbs Announces Publication in Cancers 16 October 2023

Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early... Read more

MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus 11 October 2023

Copenhagen, Denmark, 11 October 2023 – MinervaX ApS, a privately held Danish biotechnology company... Read more

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology 21 September 2023

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company”... Read more

MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults 28 June 2023

Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults... Read more

Minutes from Annual General Meeting 08 June 2023

The Annual General Meeting in DANISH BIO-DANSK BIOTEK was held on 11 May 2023 at Børsen. The Minutes... Read more

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO 26 May 2023

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more

Y-mAbs Announces Presentation of Naxitamab Data at ASCO 26 May 2023

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil 23 May 2023

May 23, 2023PDF VersionNEW YORK, May 23, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics,... Read more

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis 23 May 2023

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology... Read more

Copyright 2023 DANISH BIO – DANSK BIOTEK. All rights reserved.

created by: Mastafu Design